Characterization of multiple driver alterations in acquired resistance to osimertinib in EGFR-mutated lung cancer: implementation of single cell approaches

被引：0
|
作者：
Chen, Jeanne [1 ]
Braye, Floriane [1 ]
Facchinetti, Francesco [1 ]
Lacroix, Ludovic [1 ]
Scoazec, Jean-Yves [1 ]
Tselikas, Lambros [1 ]
Planchard, David [1 ]
Mezquita, Laura [1 ]
Gazzah, Anas [1 ]
Naltet, Charles [1 ]
Lavaud, Pernelle [1 ]
Maillard, Aline [1 ]
Michiels, Stefan [1 ]
Massard, Christophe [1 ]
Olaussen, KenA [1 ]
Andr, Fabrice [1 ]
Vassal, Gilles [1 ]
Soria, Jean-Charles [1 ]
Besse, Benjamin [1 ]
Friboulet, Luc [1 ]
机构：
[1] Inst Gustave Roussy, Villejuif, France
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-1867
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1867
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Osimertinib in EGFR-Mutated Lung Cancer REPLY
    Herbst, Roy S.
    Wu, Yi-Long
    Tsuboi, Masahiro
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (07): : 675 - 676
  • [2] Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
    Alessandro Leonetti
    Sugandhi Sharma
    Roberta Minari
    Paola Perego
    Elisa Giovannetti
    Marcello Tiseo
    British Journal of Cancer, 2019, 121 : 725 - 737
  • [3] Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
    Leonetti, Alessandro
    Sharma, Sugandhi
    Minari, Roberta
    Perego, Paola
    Giovannetti, Elisa
    Tiseo, Marcello
    BRITISH JOURNAL OF CANCER, 2019, 121 (09) : 725 - 737
  • [4] Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-Mutated Non-small Cell Lung Cancer
    Lee, Jiyun
    Shim, Joon Ho
    Park, Woong-Yang
    Kim, Hee Kyung
    Sun, Jong-Mu
    Lee, Se-Noon
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    CANCER RESEARCH AND TREATMENT, 2019, 51 (01): : 408 - 412
  • [5] Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?
    Bertoli, Elisa
    De Carlo, Elisa
    Del Conte, Alessandro
    Stanzione, Brigida
    Revelant, Alberto
    Fassetta, Kelly
    Spina, Michele
    Bearz, Alessandra
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (13)
  • [6] Managing Acquired Resistance in EGFR-Mutated Non-Small Cell Lung Cancer
    Forde, Patrick M.
    Ettinger, David S.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (08) : 528 - 532
  • [7] Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer
    Wu, Yi-Long
    Tsuboi, Masahiro
    He, Jie
    John, Thomas
    Grohe, Christian
    Majem, Margarita
    Goldman, Jonathan W.
    Laktionov, Konstantin
    Kim, Sang-We
    Kato, Terufumi
    Vu, Huu-Vinh
    Lu, Shun
    Lee, Kye-Young
    Akewanlop, Charuwan
    Yu, Chong-Jen
    de Marinis, Filippo
    Bonanno, Laura
    Domine, Manuel
    Shepherd, Frances A.
    Zeng, Lingmin
    Hodge, Rachel
    Atasoy, Ajlan
    Rukazenkov, Yuri
    Herbst, Roy S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (18): : 1711 - 1723
  • [8] Adjuvant Osimertinib in EGFR-Mutated Non-Small-Cell Lung Cancer
    Planchard, David
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (18): : 1780 - 1782
  • [9] Safety of osimertinib in EGFR-mutated non-small cell lung cancer
    Mezquita, Laura
    Varga, Andreea
    Planchard, David
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (12) : 1239 - 1248
  • [10] MERTK Activation Drives Osimertinib Resistance in EGFR-Mutated Non-Small Cell Lung Cancer
    Yan, D.
    Huelse, J.
    Parker, R.
    Wang, X.
    Frye, S.
    Earp, H. S.
    Deryckere, D.
    Graham, D.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : S1147 - S1147
12345